BUSINESSES AND INNOVATIONS – Orange County Business Journal

BUSINESSES AND INNOVATIONS – Orange County Business Journal

MONEY

Thrivelab Co.a San Clemente hormone replacement therapy telehealth provider, has closed a $4 million seed round led by diagnostics firm Discover labsCEO Joshua’s Host he told the Business Journal.

The funding will allow Thrivelab to expand its services nationally; the company’s offerings are currently available in 30 states. The money also enables Thrivelab to cut its current treatment time by 28% and support the company’s next phase of diagnostic machine learning, Host said.

Thrivelab says its services reduce the cost of hormone replacement therapy by 70% and reduce treatment time by 65%. The company plans to scale its patient intake from 1,000 per month to 5,000 per month in the next half year.

Host founded Thrivelab in 2020 after bioidentical hormone replacement therapy helped him recover from brain injuries he sustained in a bicycle accident about seven years ago. The host also serves as CEO of the Laguna Beach hospitality company. antiresort and San Clemente real estate Mariachi Cover Band LLC. He previously co-founded the Irvine mixed-use project developer Urban Village Development Company LLC. Host served as CEO of the mortgage company my loan hostwhich was sold in 2006, according to Host’s LinkedIn.

Amplifies Holdings Group Inc.a San Diego biopharmaceutical company with ICU ties, recently closed an $11.8 million Series A preferred stock financing facilitated by SternAegis Ventures.

The funding will allow the company to further develop its treatment for hair loss in men and women.

“Investor participation in this funding round exceeded our Series A target, highlighting the unmet need in the market for a solution to the hair loss challenge, as well as enthusiasm for Amplifica’s novel approach and therapeutics. first class to address this issue. problem,” CEO and President Frank Fazio said in a statement.

Amplifica’s technology aims to employ signaling molecules that stimulate dormant hair follicle stem cells, leading to hair regrowth, company officials said. The company hopes to launch its first clinical program next year.

Amplify was co-founded by UCI biology professor Maksim Plikus, whose research has indicated that a molecule called SCUBE3 can stimulate new hair growth.

Fazio, the company’s CEO, also serves as CEO of the consulting organization AMC Group. Previously, he held several iterations of the senior vice president and corporate development role at dietary supplement and food ingredient company ChromaDex Corp. (Nasdaq: CDXC), which has ties to OC as well as skin care manufacturing company Irvine skincare, ZO Skin Health Inc., and esthetics company Medico Sunna.

THROW

LaWow LLCa Laguna Niguel legal software company, has unveiled its consumer-friendly lawsuit search engine, the first of its kind, the company says.

The platform is intended to be a resource for journalists, researchers, employees, stock investors and others who are curious about the lawsuits, company officials said.

“We think public information should be public, but if the government charges fees for access, is it really public?” anderson-zouDirector of lawWowhe said in a statement. “I saw a lot of breaking news that was about lawsuits, but I always had a hard time finding the actual document. It seemed like a huge ‘information gap’ to me on the internet… so we set out to fix it.

“This public utility is long overdue… an unbiased, fact-based news and information source is critical now more than ever,” added Zou.

The company, founded this year, recently completed a $2.2 million funding round led by Dant Ventures LLCwhich is owned by the holding company Actuarial Management Corporationaccording to company officials.

The company is currently expanding its team of developers, officials at laWow said.

His team currently has 18 employees totaling around 5,000 cases per day, co-founder of laWow Jonathan Wallentinwho is the CEO of Actuarial Management, told the Business Journal.

The search engine currently has more than 30,000 cases.

“We are trying to democratize the legal system,” he said.

Zou previously served as vice president of corporate development at Actuarial Management. He was an academic researcher at Columbia Law School.

FUSIONS AND ACQUISITIONS

Agile PC for occupational medicinea Costa Mesa-based clinic company focused on providing care to injured workers, entered Northern California with the acquisition of Occupational Medicine of Emergyville.

The deal adds four clinics in Emeryville, Sacramento, Redding and Santa Cruz to Agile’s portfolio. Agile now has six clinics after the acquisition.

“These clinics fill a need in underserved communities, especially in Redding and Santa Cruz, where employers need more access to quality care,” founder and CEO of Agile Greg Moore he said in a statement.

Agile is focused on forming partnerships with local businesses to ensure the medical needs of local employees are addressed, the company said. Provides Department of Transportation physicals, drug tests, and treatment for workplace injuries.

In May, the company raised an undisclosed amount in a funding round led by Angeles Equity Partners. His goal is to grow his portfolio to at least 30 clinics in the next two years, Director of Communications Ken Thompson he told the Business Journal.

Moore, who founded Agile last year, previously ran a fast-growing network of occupational clinics. Akeso Occupational Health. Most of the Agile C-suite comes from Irvine-based Akeso, Thomspon said. Moore was also CEO of the Irvine Medical Network Tool Provider. port health systemswhich was acquired by a medical call inc. in 2012.

REGULATOR

NKGen Biotech Inc.a Santa Ana biotech company that develops natural cell therapies to boost the immune system, has received FDA Research New Drug Authorization to begin a Phase 1 study of its cell therapy for cancer patients whose diseases are resistant to the standard of current care.

The study will evaluate the safety and tolerability of NKGen cell therapy, SNK02, which is cryopreserved and derived from blood, according to company officials. NKGen expects the study to start in the first quarter of next year.

“This authorization for SNK02 is an important milestone in our quest to bring life-changing therapies to cancer patients and will be our second solid tumor-focused NK cell therapy clinical program, following our autologous product SNK01 entering the pipeline. phase 2 studies next year”, NKGen vice president paul’s song he said in a statement.

NKGen Biotech has raised $11 million in funding to date. The company, a subsidiary of the Korean biotechnology company. NKMax Co.was founded in 2019 by Sangwoo Park. Park also founded NKMax, which is traded overseas and is valued at $226 million, three years ago. He previously worked as a financial analyst in wealth management Samsung Securities Co.

Leave a Comment